IL-2 CD80 FORMULATIOM OF FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN

The present invention relates to a pharmaceutical formulation having improved stability of a fusion protein dimer containing modified IL-2 and CD80 proteins. The fusion protein dimer containing IL-2 and CD80 proteins can not only activate immune cells by IL-2, but also effectively regulate Treg cell...

Full description

Saved in:
Bibliographic Details
Main Authors OH YOUNG MIN, CHO YOUNG GYU, KWON SOONTAK, LIM HEONCHANG, JANG MYOUNG HO, NAM SU YOUN
Format Patent
LanguageEnglish
Korean
Published 28.09.2021
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a pharmaceutical formulation having improved stability of a fusion protein dimer containing modified IL-2 and CD80 proteins. The fusion protein dimer containing IL-2 and CD80 proteins can not only activate immune cells by IL-2, but also effectively regulate Treg cells by CD80. The application of the formulation according to the present invention to the fusion protein dimer containing IL-2 and CD80 proteins not only can significantly improve the stability of the fusion protein dimer, but can also be used as a liquid formulation, leading to high commercial usability of the fusion protein dimer. 본 발명은 변형된 IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체의 안정성을 향상시킨 약제학적 제형에 관한 것이다. IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체는 IL-2에 의해 면역세포를 활성화시킬 수 있을 뿐 아니라, CD80에 의해 Treg 세포를 효과적으로 조절할 수 있다. 본 발명에 따른 제형을 IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체에 적용할 경우 상기 융합단백질 이량체의 안정성이 현저히 증가할 뿐 아니라, 액상 제형으로 이용 가능하므로 융합단백질 이량체의 상업적 활용성을 높일 수 있다.
Bibliography:Application Number: KR20210034747